News
![Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
![Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
![Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
![Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
![Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
![Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
![Lonza Appoints Wolfgang Wienand as New Chief Executive Officer](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
![Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
![Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
![Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
![Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
![Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
![Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
![Board Announcement](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Board Announcement
Board Announcement
![Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
![Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory
![Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
![Lonza Increases Straight Bond by CHF 150 Million](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Increases Straight Bond by CHF 150 Million
Lonza Increases Straight Bond by CHF 150 Million
![Lonza Launches Share Buyback Program of up to CHF 2 Billion](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
![Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
![Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
![Lonza Completes Expansion of Conjugation Facility in Visp (CH)](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
![Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
![Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
![Lonza and Touchlight collaborate on end-to-end mRNA offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lonza and Touchlight collaborate on end-to-end mRNA offering
Lonza and Touchlight collaborate on end-to-end mRNA offering